The US oncology biosimilar market has rapidly evolved since its launch in 2017, driven by steep price discounts, payer ...

Korean drugmakers hold over 50% market share in the 6 best-selling biosimilar markets, 2 companies sign exclusive licensing ...

Reforming patent litigation to mirror successful outcomes across Europe could significantly accelerate US biosimilar market ...

The phase 3 trial showed biosimilar CT-P42 (Celltrion) is therapeutically equivalent to reference aflibercept in improving ...

Number 5: The top 5 biosimilar-related articles of the year highlight a significant shift in the pharmaceutical industry, ...

Celltrion’s denosumab biosimilar demonstrated equivalent efficacy, safety, and immunogenicity compared with the originator in a phase 3 trial involving postmenopausal women with osteoporosis, paving ...

Celltrion’s denosumab biosimilar demonstrated equivalent efficacy, safety, and immunogenicity compared with the originator in ...

The top 5 biosimilar-related articles of the year highlight a significant shift in the pharmaceutical industry, with ...

To close out the year, 4 senators came together to introduce a new bipartisan bill to protect biosimilar and generic drug ...

The phase 3 trial showed biosimilar CT-P42 (Celltrion) is therapeutically equivalent to reference aflibercept in improving ...

The 2024 surge in FDA approvals for aflibercept biosimilars reflects significant progress in offering cost-effective treatments for retinal conditions like neovascular age-related macular degeneration ...